Duke Royalty Limited, a Guernsey-based public diversified royalty company, and Oliver Wyman announced this week a financing collaboration in the rapidly developing pharmaceutical and healthcare-related royalty market. This unique collaboration brings together a global, respected source of deep healthcare knowledge with a publicly-quoted royalty company to create a unique offering to healthcare companies and public investors alike.
- Exclusive arrangement aligns both Duke Royalty and Oliver Wyman interests to unlock value, growth, and innovation by offering royalty financing solutions
- Long-term commitment, signifying belief and dedication to the opportunity for healthcare companies and investors
- Leverages Oliver Wyman’s global presence, deep healthcare expertise, and proprietary datasets and methodologies to offer a financing alternative from a trusted advisor
- Collaboration details significant commitment from both parties to drive success for both healthcare innovators seeking capital and investors seeking yield
We have built intellectual capital, a proprietary methodology and datasets, and a track record that will provide critical forecasting and risk assessments for investors and companies seeking capital. - Oliver Wyman's David Campbell
Duke Royalty brings the quoted royalty financing structure, a $30 billion sector in North America, to the attractive and yet-to-be-developed European market. Having advised on more than $2 billion healthcare royalty transactions in North America, the Investment Committee members of Duke Royalty bring their expertise to the European market. Duke Royalty will be responsible for capital raising, the structuring of definitive agreements, and the acquisition of each royalty interest originating from the collaboration.
Duke Royalty believes it has improved upon the classic Canadian public company royalty model in two ways: firstly, through exclusive strategic partnerships that bring deal flow and unmatched expertise, and secondly, by employing a time-tested corporate structure in Guernsey that is designed to provide higher returns to shareholders.
Commenting on the collaboration, Neil Johnson, CEO of Duke Royalty, said: “North America has built a number of highly successful and significant sized royalty companies in both the private and listed arenas. The Duke Royalty and Oliver Wyman collaboration will provide this progressive and compelling financing structure to the global healthcare industry. We are excited to present a new opportunity for healthcare companies to receive capital yet retain control, and look forward to providing UK public investors predictable revenues and a stable dividend.”
Oliver Wyman brings its global network of professionals, with a deep bench of clinical, health system, and risk experts and a successful track record of valuing biopharmaceutical and other healthcare intellectual property for its Fortune 1000 clientele. With offices around the world, there are over 200 professionals in the Health & Life Sciences Practice of Oliver Wyman.
Under the terms of the collaboration, Oliver Wyman will identify, analyse, and assist in the acquisition of royalty interests for regulatory-approved, patent-protected ethical pharmaceutical and other healthcare products. We have built intellectual capital, a proprietary methodology and datasets, and a track record that will provide critical forecasting and risk assessments for investors and companies seeking capital.